DOCTORATE in GENETICS, ONCOLOGY and CLINICAL MEDICINE (GenOMeC)
DOTTORATO DI RICERCA IN GENETICA ONCOLOGIA E MEDICINA CLINICA

UNIVERSITA' DEGLI STUDI  DI SIENA

                                                                                        Home Page
 

Publications during the PhD program
 
Forte Iris Maria    
 

1) HOX D13 expression across 79 tumor tissue types.

Cantile M, Franco R, Tschan A, Baumhoer D, Zlobec I, Schiavo G, Forte I, Bihl M, Liguori G, Botti G, Tornillo L, Karamitopoulou-Diamantis E, Terracciano L, Cillo C.

2009 Oct 1;125(7):1532-41.

 

2) Rb family proteins in gastric cancer (review).

Cito L, Pentimalli F, Forte I, Mattioli E, Giordano A.

Oncol Rep. 2010 Dec;24(6):1411-8.

 

3) Parallel determination of NeuroD1, chromogranin-A, KI67 and androgen receptor expression in surgically treated prostate cancers.

Cindolo L, Cantile M, Franco R, Chiodini P, Schiavo G, Forte I, Zlobec I, Salzano L, Botti G, Gidaro S, Terracciano L, Cillo C.

2011 Jan-Feb;37(1):57-66.

 

4) New pyrazolo[3,4-d]pyrimidine SRC inhibitors induce apoptosis in mesothelioma cell lines through p27 nuclear stabilization.

Indovina P, Giorgi F, Rizzo V, Khadang B, Schenone S, Di Marzo D, Forte IM, Tomei V, Mattioli E, D'Urso V, Grilli B, Botta M, Giordano A, Pentimalli F.

Oncogene. 2011 Jul 25.

 

5) Antitumor activity of new pyrazolo[3,4-d]pyrimidine SRC kinase inhibitors in Burkitt lymphoma cell lines and its enhancement by WEE1 inhibition.

Cozzi M, Giorgi F, Marcelli E, Pentimalli F, Forte IM, Schenone S, D'urso V, De Falco G, Botta M, Giordano A, Indovina P.

Cell Cycle. 2012 Mar 1;11(5).

 

6) Modeling human osteosarcoma in mice through 3AB-OS cancer stem cell xenografts.
Di Fiore R, Guercio A, Puleio R, Di Marco P, Drago-Ferrante R, D'Anneo A, De Blasio A, Carlisi D, Di Bella S, Pentimalli F, Forte IM, Giordano A, Tesoriere G, Vento R.
2012 Nov;113(11):3380-92.

7) Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.
Di Marzo D, Forte IM, Indovina P, Di Gennaro E, Rizzo V, Giorgi F, Mattioli E, Iannuzzi CA, Budillon A, Giordano A, Pentimalli F.
 2014;13(4):652-65. doi: 10.4161/cc.27546.

8) Abrogating G2/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma.
Indovina P, Marcelli E, Di Marzo D, Casini N, Forte IM, Giorgi F, Alfano L, Pentimalli F, Giordano A.
2014 Apr;15(4):380-8. doi: 10.4161/cbt.27623.

9) Antineoplastic activity of povidone-iodine on different mesothelioma cell lines: results of in vitro study.
Fiorelli A, Pentimalli F, D'Urso V, Di Marzo D, Forte IM, Giordano A, Di Domenico M, Accardo M, Di Serio U, Santini M.
2014 Jun;45(6):993-1000.
10) MicroRNA-29b-1 impairs in vitro cell proliferation, self-renewal and chemoresistance of human osteosarcoma 3AB-OS cancer stem cells.
 Di Fiore R, Drago-Ferrante R, Pentimalli F, Di Marzo D, Forte IM, D'Anneo A, Carlisi D, De Blasio A, Giuliano M, Tesoriere G, Giordano A, Vento R.
I 2014 Nov;45(5):2013-23.

11) pRb2/p130 localizes to the cytoplasm in diffuse gastric cancer.
Cito L, Indovina P, Forte IM, Pentimalli F, Di Marzo D, Somma P, Barone D, Penon A, Penon D, Ceccherini E, Micheli P, Saragoni L, Di Domenico M, Feola A, Roviello F, Mattioli E, Giordano GG, Giordano A.
 2015 Apr;230(4):802-5.

12) SRC family kinase inhibition through a new pyrazolo[3,4-d]pyrimidine derivative as a feasible approach for glioblastoma treatment.
Ceccherini E, Indovina P, Zamperini C, Dreassi E, Casini N, Cutaia O, Forte IM, Pentimalli F, Esposito L, Polito MS, Schenone S, Botta M, Giordano A.
2015 May;116(5):856-63.

13) SRC family kinase (SFK) inhibition reduces rhabdomyosarcoma cell growth in vitro and in vivo and triggers p38 MAP kinase-mediated differentiation.
Casini N, Forte IM, Mastrogiovanni G, Pentimalli F, Angelucci A, Festuccia C, Tomei V, Ceccherini E, Di Marzo D, Schenone S, Botta M, Giordano A, Indovina P.
2015 May 20;6(14):12421-35.